肝纤维化治疗进展

Research Progress in Treatment of Liver Fibrosis

肝纤维化(HF)是继发于各种慢性肝损伤的一种组织修复过程,以肝星形细胞(HSC)激活和细胞外基质(ECM)过多产生为病理特征。HF是向肝硬化甚至原发性肝癌发展的一个中间环节。HF的早期治疗可以逆转或抑制其发展。因此,能否延缓、阻断或逆转HF的发展,具有重大意义。近年来抗HF药物的研究已进入细胞分子水平,少数已深入到细胞内信息控制水平。旨在通过抑制HSC的激活、诱导其凋亡和防止ECM沉积的干预性治疗在实验性阶段已取得疗效,但抗HF的临床有效性和安全性有待于进一步研究和论证。

Hepatic fibrosis（HF） is a tissue repair process which secondary to a variety of chronic liver injury. Activation of hepatic stellate cells （ HSC ） and excess produce of extracellular matrix （ ECM ） are the pathological featureS. As we know, HF can develop into liver cirrhosis and primary liver cancer, early treatment of HF can reverse or inhibit this process. Therefore, the ability to delay, block or reverse the development of HF is of great significance. In recent years,the study of anti-HF drugs has focused on the effect on the target cells and molecules,a few bad reached the level of information control in cells. Intervention therapy such as inhibiting HSC activation,inducing HSC apoptosis and preventing ECM deposition has been proved efficacy in the experiment stage, however, the efficacy and safety of anti-HF need to be further studied and verified.